

The 8th Bioscience Economy Conference

**June 18, 2002
Geneva – Switzerland**

**June 19-20, 2002
Milano – Italy**



Sponsored by:



Organized by:



MARAZZI RONCOLI ZOTTI & PARTNERS



The 8th Bioscience Economy Conference

PROGRAM

Wednesday, June 19, 2002 - Centro Congressi Svizzero - Milano

- 09:00 **Registration**
- 09:15 **Welcome** Chairman Ettore dell'Isola, General Manager, CIRC
Dario A. Bianchi, Siena Financial Services and Capitalife
- 09:30 **Aastrom Biosciences, Inc.** R. Douglas Armstrong, President and Chief Executive Officer
- 10:15 **Diversa Corporation** Karin Eastham, Chief Financial Officer and
Senior Vice President, Finance
- 11:00 **Regeneron Pharmaceuticals, Inc.** Hans-Peter Guler, Vice President, Clinical Sciences
- 11:45 **Intermune Pharmaceuticals, Inc.** John Donovan, Director, Investor Relations and
Strategic Planning
- 12:30 **Lunch**
- 13:45 Introduction to the afternoon session **"The Bioscience Economy: from Science to Business"**
Moderators Paolo Barbanti, Professor at University of Bologna
Luca Guidotti, Associate Professor, Scripps Research Institute
- 14:15 **Claudio Bordinon** Direttore Scientifico, Istituto Scientifico San Raffaele, Milano
- 15:00 **Carlo Vanoli** Chief Operating Officer, SNIA
Ettore dell'Isola General Manager, CIRC (Centro per l'Innovazione e la Ricerca Chimica)
- 15:30 **Marco Nicolai** General Manager, Finlombarda S.p.A.
Fabio Marazzi Marazzi Roncoli Zotti & Partners
- 16:00 **Pio De Gregorio** Head of Equity Research, UniCredit Banca Mobiliare (UBM)
Dario A. Bianchi Managing Director, Siena Financial Services and Capitalife
- 16:30 – 17:15 Round table and conclusive remarks

Thursday, June 20, 2002 - Centro Congressi Svizzero - Milano

- 09:00 **Welcome** Chairman Pio De Gregorio, Head of Equity Research, UBM
- 09:15 **Neose Technologies, Inc.** Matthew Kremer, Senior Director of Corporate
Communications
- 10:00 **Nicox S.A.** Michele Garufi, Chairman and Chief Executive Officer
- 10:45 **Neurocrine Biosciences, Inc.** Gary A. Lyons, President and Chief Executive Officer
- 11:30 **Thuris Corporation** Gary Lynch, Co-Founder and Chairman
- 12:15 Round table **"New breakthroughs in neurosciences"**
Moderator **Giorgio Riveccio**, the Editor, Newton Magazine, R.C.S.
Gary A. Lyons, President and CEO, Neurocrine Biosciences, Inc.
Gary Lynch, Professor Above Scale, Psychiatry Department, University of
California, Irvine and Co-Founder and Chairman of Thuris Corporation
Antonino Cattaneo, Professor of Biophysics at the International School for
Advanced Studies (SISSA), Trieste and President of Lay Line Genomics S.p.A.
- 13:00 Conclusive Lunch

The 8th Bioscience Economy Conference
Centro Congressi Svizzero, Via Palestro, 2 – Milano
For further information please contact:
Marco Bottaro – Siena Financial Services – tel. +39 348 0456 709

PARTICIPANTS: SHORT COMPANY PROFILE

■ AASTROM BIOSCIENCES, INC.

Aastrom (Nasdaq: ASTM) is a leader in the development of novel cell therapy technology and products for immunotherapy and tissue regeneration. The Company's lead products include proprietary stem cell mixtures for tissue repair (OCG-I for bone grafting; SC-I for blood and immune system regeneration) and dendritic cells for use as cancer vaccines. These cells are produced using the AastromReplicell™ System, a proprietary automated cell manufacturing platform which is CE Mark approved for European marketing and sales.

For further information, please visit www.aastrom.com

■ DIVERSA CORPORATION

Diversa (Nasdaq: DVSA) is located in San Diego, in the midst of the world's fastest growing biotech area, near the University of California, Salk Institute and Scripps Research Institute. Diversa Corporation is a global leader in developing and applying proprietary technologies to discover and evolve novel genes and gene pathways to develop products for the pharmaceutical, agricultural, chemical processing, and industrial markets. Within these broad markets Diversa is targeting key multi-billion dollar market segments where the Company believes its technologies and products will create high value and competitive advantages for strategic partners and customers.

For further information, please visit: www.diversa.com

■ NEOSE TECHNOLOGIES, INC.

Neose Technologies, Inc. (Nasdaq: NTEC) develops proprietary technologies for the synthesis and manufacture of complex carbohydrates. The company uses its broad technology platform in the following programs: GlycoAdvance™ products and services for correcting incomplete or incorrect glycosylation encountered in the manufacture of recombinant glycoproteins; GlycoTherapeutics™ to develop and produce novel carbohydrate-based therapeutics; and GlycoActives™ to develop novel carbohydrate-based food and nutritional ingredients.

For further information, please visit: www.neose.com

■ NEUROCRINE BIOSCIENCES, INC.

Neurocrine Biosciences (Nasdaq: NBIX) is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Neurocrine's product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, stroke, and certain female health disorders. The Company currently has seven potential products in clinical development and a broad research pipeline to deliver potential next-generation products. The lead clinical development program is in Phase III clinical trials for the treatment of insomnia.

For further information, please visit: www.neurocrine.com

■ NICOX

NicOx is an emerging pharmaceutical company using recently-discovered properties of nitric oxide to design and develop safer and more effective drugs. NicOx is targeting several major pharmaceutical markets including pain and inflammation, cardiovascular diseases, respiratory disorders, inflammatory bowel diseases, urinary incontinence, osteoporosis, certain dermatological disorders, certain liver diseases, Alzheimer's disease and colon cancer. Headquartered in Sophia-Antipolis, France, NicOx is a Public Company listed on the Nouveau Marché of Euronext Paris (Segment: Next Economy).

For further information, please visit: www.nicox.com

■ REGENERON PHARMACEUTICALS, INC.

Regeneron (Nasdaq: REGN) is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron incorporated its proprietary technologies into a comprehensive process designed to understand the biology of specific diseases, discover potential therapeutic candidates and evaluate them in clinical trials. Regeneron's lead product candidate, AXOKINE®, a re-engineered version of a naturally occurring protein hormone for the potential treatment of obesity, is currently in phase III clinical testing. Additional product candidates are progressing through different stages of human clinical trials, for the potential application in a diverse set of diseases, including obesity, rheumatoid arthritis, and cancer.

For further information, please visit: www.regeneron.com

■ INTERMUNE PHARMACEUTICALS, INC.

InterMune (Nasdaq: ITMN) develops and commercialize innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune has three marketed products, growing product revenues and advanced-stage clinical programs addressing a range of diseases with attractive commercial markets. The three marketed products are: Actimmune, Infergen and Amphotec. Actimmune is approved in the United States for two rare congenital disorders such as. Chronic granulomatous disease and severe, malignant osteopetrosis. Infergen is marketed in the United States and Canada for the treatment of chronic hepatitis C infections. Amphotec is marketed worldwide for the treatment of invasive aspergillosis.

For further information, please visit: www.intermune.com

■ THURIS CORPORATION

Thuris is an integrated biopharmaceutical company that has developed animal models that recreate the hallmarks (including neurofibrillary tangles and amyloid toxicity) of Alzheimer's Disease in just six days - a huge leap forward for neurodegenerative drug development. These advances have enabled Thuris to focus on developing mechanism-based compounds to treat Alzheimer's disease and related neurodegenerative disorders. Thuris is engaged in a major drug co-development project with Cephalon and has two other drug development projects. The company is also developing a non-invasive medical device that will assist in the diagnosis of psychiatric and neurological disorders over a broad range of brain-related conditions.

For further information, please visit: www.thuris.com

The 8th Bioscience Economy Conference

June 18, 2002 - Hotel Metropole - 34, quai du General Guisan, CH-1211, Geneva, Switzerland
June 19 and 20, 2002 - Centro Congressi Svizzero - Via Palestro 2, Milano, Italy

REGISTRATION FORM

Dr./ Mr./ Ms. _____

Title / Position _____

Company _____

Street and postal code _____

City, Country _____

Telephone _____ Fax _____

E-mail address _____ @ _____

Website address WWW. _____

Signature _____

(confirms right to publish information, making it available to "The 8th Bioscience Economy Conference" attendees)

Yes, I want to attend the "8th Bioscience Economy Conference" on:

☐ June 18, Geneva

☐ June 19, Milano

☐ June 20, Milano

Please fill in the required information and fax or e-mail to the attention of:

Dr.ssa Marina Giacomelli · Fax: +39 02 34565 339
E-mail: marina.giacomelli@circmi.it

A completely filled copy of this registration form is required for each delegate.
The admission to "The 8th Bioscience Economy Conference" is by invitation only.
No registration fee is required.

For any further information please contact:

Dr. M. Bottaro, Siena Financial Services and Capitalife,
Dr.ssa M. Giacomelli, Club delle Tecnologie, CIRC,

tel. +39 348 0456 709
tel. +39 02 34565 315
or +39 02 34565 271